Skip to main content

Table 4 Baseline and relapse levels of ALT and HBV DNA in patients with relapse

From: Long-term outcomes after nucleos(t)ide analogues discontinuation in chronic hepatitis B patients with HBeAg-negative

No. NUCs HBV DNA - log10 IU/mL ALT - ULN Retreat
   Baseline Relapse Baseline Relapse  
1 LAM 7.70 3.39 1.67 1.02 ETV
2 LAM 7.67 3.51 3.88 1.45 ETV
3 ADV 3.91 3.35 1.43 0.57 ADV
4 ADV 4.14 3.74 2.71 0.74 ADV
5 ADV 5.88 3.41 1.48 0.36 ADV
6 ADV 5.42 5.71 7.33 4.90 ADV
7 ADV 7.71 3.41 8.00 0.83 ADV
8 ADV 3.87 3.44 1.26 1.00 ADV
9 ADV 6.32 3.43 1.31 0.98 ADV
10 ADV 5.39 3.77 1.05 0.36 ADV
11 ADV 5.86 4.06 6.69 1.21 ADV
12 ADV 3.33 3.39 1.38 0.90 ADV
13 ADV 6.37 3.60 5.07 1.31 ADV
14 ADV 5.68 4.51 6.57 1.57 ADV
15 ADV 4.42 4.15 1.08 0.98 ADV
16 ADV 4.68 3.31 1.32 0.17 ADV
17 ADV 7.39 4.06 3.55 0.60 ADV
18 ETV 4.55 5.22 2.74 1.07 ETV
19 ETV 5.63 3.68 1.19 1.29 ETV
  1. LAM, lamivudine; ADV, adefovir; ETV, entecavir.